Recombinant Technologies (RTL), a start up biotechnology company based in Cheshire, CT, has been involved in the discovery of a new small molecule therapy to treat Alzheimer's Disease. Being a 100% privately held firm, RT has been successful in acquiring grants from National Institute on Aging, a branch of National Institutes of Health of the Department of Health and Human Services (DHHS), Bethesda, Maryland. Recently, Connecticut Innovations Inc, a quasi government agency based in Rocky Hill, CT, has awarded RT with a matching grant to expedite the research efforts.
Alzheimer's Disease (AD) is a neurodegenerative disease that causes dementia among the elderly population, affecting about 30 million people worldwide. In industrialized nations, AD is the fourth most common cause of death. It is expected that the number of affected people will double over the next 20 years. AD is a growing problem that takes a monetary, emotional and human toll.
The treatment of AD is an unmet medical need for which no therapies have been shown to work. RTl's research over the past decade has led to a drug molecule. RT has been able to get 'proof of concept' in an animal model of AD by this therapeutic drug utilizing the funds so far. The drug molecule is a promising candidate for Alzheimer's since it has been shown to complex and eliminate the toxic abeta molecules toxic molecules that deposit in the brain causing memory loss and other degenerative symptoms of AD] from the system. In addition the drug is shown to have reduced abeta levels in the brain of treated AD model mice. Memory parameters have improved in the treated mice.
The next step is to test the safety and kinetics of this drug molecule during long term consumption using animal models, says Pazhani Sundaram, the Founder-President of the firm, who was trained at Yale for over a decade prior to starting this company in 2000. He said the advantages of working with this molecule is that it is a non-immune based, biologically tolerated small molecule that is yet to show any undesirable side effects. Numerous immune based monoclonal antibodies were discontinued during human clinical trials because of their potent side effects and mortality rates.
Dr. Sundaram graduated from the University of Madras, India where his PhD thesis work was on the research and development of a herbal medicine to treat coronary heart disease. The drug he researched on is approved in India and USA. He says he is excited to be able to come up with this new therapeutic candidate for Alzheimer's. He further said the RT is exploring many avenues to expedite the completion of the research phase and move on to the clinical trials potentially in partnership with an established biopharmaceutical company such as Pfizer, Bristol Meyers or J & J and that he will make the move when the terms and time are appropriate. Two publications in Current Alzheimers Research and International Journal of peptide Research Therapeutics detail the scientific findings from RT. RT own the IP rights to the therapy (patent pending with USPTO)External URL →